Trial Radar IA

Discutiamo ed esploriamo gli studi clinici con Bavarian Nordic come promotore principale o collaboratore.

Posso aiutarti a capire le condizioni di salute, i trattamenti o a trovare studi clinici vicini.
47 studi clinici
 
Tipo
Biologico
×
 
Titolo dello studio
Stato
An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults NCT07467707
Non ancora in arruolamento
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells NCT07199569
In arruolamento
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. NCT07003984
In arruolamento
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine NCT06899802
Attivo, non in arruolamento
Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC (PregInPoxVac) NCT06844500
Attivo, non in arruolamento
Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC (PregInPoxVac) NCT06844487
In arruolamento
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination NCT06007183
Attivo, non in arruolamento
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years NCT05349617
CompletatoRisultati pubblicati
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 NCT05329220
CompletatoRisultati pubblicati
MVA-BN-RSV Vaccine Trial NCT05238025
TerminatoRisultati pubblicati
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects NCT05077267
CompletatoRisultati pubblicati
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine) NCT05072080
CompletatoRisultati pubblicati
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine (CHIKV VLP) NCT05065983
CompletatoRisultati pubblicati
Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults NCT04752644
Completato
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer NCT04246671
Completato
A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer NCT04134312
Completato
Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects NCT04131595
Completato
Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) (WRAIR) NCT03992872
CompletatoRisultati pubblicati
Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial NCT03699124
CompletatoRisultati pubblicati
CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer NCT03628716
CompletatoRisultati pubblicati
Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix NCT03610581
TerminatoRisultati pubblicati
BN Brachyury and Radiation in Chordoma NCT03595228
CompletatoRisultati pubblicati
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC NCT03547999
TerminatoRisultati pubblicati
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer NCT03532217
Completato
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults NCT03483961
CompletatoRisultati pubblicati
Special Access Program IMVAMUNE® NCT03472014
CompletatoRisultati pubblicati
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma NCT03376659
TerminatoRisultati pubblicati
Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury) NCT03349983
Completato
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity NCT03220737
CompletatoRisultati pubblicati
JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo NCT02977715
Attivo, non in arruolamento
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults NCT02873286
CompletatoRisultati pubblicati
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults. NCT02864628
Ritirato
A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer NCT02840994
Completato
Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy NCT02772562
TerminatoRisultati pubblicati
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo NCT02661464
TerminatoRisultati pubblicati
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer NCT02506114
TerminatoRisultati pubblicati
Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine NCT02419391
Completato
Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers NCT02391909
Completato
A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults NCT02100631
CompletatoRisultati pubblicati
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults NCT02094586
CompletatoRisultati pubblicati
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection NCT02038881
CompletatoRisultati pubblicati
A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® NCT01913353
CompletatoRisultati pubblicati
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera NCT01895855
CompletatoRisultati pubblicati
A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects NCT01668537
CompletatoRisultati pubblicati
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 NCT01585181
Completato
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect) NCT01322490
CompletatoRisultati pubblicati
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy NCT01152398
Completato